Clinical Trial Update: 28-Day Study of SAGE-718 on Functioning Capacity in Participants With Huntington's Disease [Phase 2]

View source ↗

Summary

Phase 2 trial of SAGE-718 in Huntington's disease completed; results have been posted.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Huntington Disease

Drugs mentioned

• SAGE-718

Snippet

Sponsor: Supernus Pharmaceuticals, Inc. | Conditions: Huntington Disease | Phase 2 | Status: COMPLETED | Results posted: 2025-05-06